Can-Fite BioPharma Ltd. (CANF) said the last patient treated under an Open Label Extension program of its concluded phase II study of Namodenoson in the treatment of hepatocellular carcinoma reported a Complete Response. The patient has now survived five years, and completed clearance of all cancer lesions.
In the first quarter of 2022, Can-Fite plans to begin patient enrollment in its phase III trial for Namodenoson in the treatment of patients with advanced hepatocellular carcinoma with underlying Child Pugh B7 cirrhosis to support a NDA.
Shares of Can-Fite BioPharma were up 63% in pre-market trade on Monday.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.